An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland, who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray

Tilden Etges, Kari Karolia, Thomas Grint, Adam Taylor, Heather Lauder, Brian Daka, Stephen Wright GW Pharmaceuticals, Cambridge, UK Abstract: The global exposure of Sativex® (Δ9-tetrahydrocannabinol [THC]:cannabidiol [CBD], nabiximols) is estimated to be above 45,000 patient-years since...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Etges T, Karolia K, Grint T, Taylor A, Lauder H, Daka B, Wright S
Format:	Artigo
Sprog:	Inglês
Udgivet:	Dove Medical Press 2016-11-01
Serier:	Therapeutics and Clinical Risk Management
Fag:	Sativex nabiximols THC:CBD multiple sclerosis spasticity registry
Online adgang:	https://www.dovepress.com/an-observational-postmarketing-safety-registry-of-patients-in-the-uk-g-peer-reviewed-article-TCRM
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!